• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Femasys Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket

    9/26/23 8:05:02 AM ET
    $ADPT
    $AKU
    $AVTX
    $BPTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ADPT alert in real time by email

    Gainers

    Femasys Inc. (NASDAQ:FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment.

    Tharimmune Inc (NASDAQ:THAR) shares rose 101.4% to $0.4450 in pre-market trading after falling around 5% on Monday.

    Infobird Co., Ltd (NASDAQ:IFBD) shares gained 31.1% to $0.1709 in pre-market trading. Infobird recently announced receipt of delinquency notification letter from the Nasdaq.

    Avalo Therapeutics, Inc. (NASDAQ:AVTX) gained 19.3% to $0.1945 in pre-market trading after jumping over 36% on Monday. The company recently announced the sale of its assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose).

    Akumin Inc. (NASDAQ:AKU) shares rose 18.4% to $0.1670 in pre-market trading.

    NexImmune, Inc. (NASDAQ:NEXI) shares surged 17% to $0.2399 in pre-market trading.

    Precision BioSciences, Inc. (NASDAQ:DTIL) rose 16.1% to $0.4280 in pre-market trading.

    Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares climbed 13.8% to $5.78 in pre-market trading. Adaptive recently announced the launch of Epic integration for clonoSEQ.

    E-Home Household Service Holdings Limited (NASDAQ:EJH) shares jumped 11.7% to $1.05 in pre-market trading.

    Blue Star Foods Corp. (NASDAQ:BSFC) rose 10.3% to $0.2560 in pre-market trading after dipping 20% on Monday.

    Losers

    TransCode Therapeutics, Inc. (NASDAQ:RNAZ) fell 67.8% to $0.8195 in pre-market trading after the company priced its $8 million public offering of 15.7 million shares at $0.51 per share.

    Murphy Canyon Acquisition Corp. (NYSE:CDT) fell 18.1% to $8.50 in pre-market trading after dipping 38% on Monday.

    Jet.AI Inc. (NASDAQ:JTAI) shares fell 17.6% to $2.53 in pre-market trading after surging 25% on Monday.

    MSP Recovery, Inc. (NASDAQ:LIFW) shares fell 13.5% to $0.1751 in pre-market trading after declining around 15% on Monday.

    Biophytis S.A. (NASDAQ:BPTS) fell 13.2% to $1.38 in pre-market trading. Biophytis shares jumped over 72% on Monday after the company and Skyepharma announced a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19.

    Polished.com Inc. (NYSE:POL) fell 12.4% to $0.1086 in pre-market trading after surging 40% on Monday.

    Sacks Parente Golf, Inc. (NASDAQ:SPGC) fell 11.7% to $1.20 in pre-market trading. The company recently posted a narrower second-quarter loss.

    FaZe Holdings Inc. (NASDAQ:FAZE) shares fell 10.4% to $0.1720 in pre-market trading after jumping 25% on Monday.

    PaxMedica, Inc. (NASDAQ:PXMD) fell 10% to $0.28 in pre-market trading after gaining 5% on Monday.

    Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) fell 9.8% to $0.0833 in pre-market after declining over 4% on Monday.

    Now Read This: TD SYNNEX, Profound Medical And 3 Stocks To Watch Heading Into Tuesday

    Get the next $ADPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADPT
    $AKU
    $AVTX
    $BPTS

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    4/9/2026$48.00Outperform
    Wolfe Research
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Adaptive Biotechnologies Corporation
    $ADPT
    12/2/2025$21.00Equal-Weight
    Morgan Stanley
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Adaptive Biotechnologies Corporation
    $ADPT
    9/30/2025$20.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    More analyst ratings

    $ADPT
    $AKU
    $AVTX
    $BPTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jet.AI Announces $5 Million SPV Economic Interest in xAI (SpaceX)

    LAS VEGAS, NV, April 08, 2026 (GLOBE NEWSWIRE) -- Jet.AI Inc. ("Jet.AI" or the "Company") (NASDAQ:JTAI), an emerging provider of high-performance GPU infrastructure and AI cloud services, today announced a $5 million strategic investment intended to provide an economic interest in SpaceX and its related subsidiaries, including but not limited to x.AI / Grok, Starlink, and X / Twitter. The investment was made through a Special Purpose Vehicle ("SPV") that held equity in xAI, prior to x.AI's recent acquisition by SpaceX. The investment is intended to reinforce Jet.AI's strategic pivot toward AI infrastructure and to gain economic exposure into SpaceX and xAI's potential performance and grow

    4/8/26 8:00:00 AM ET
    $JTAI
    Transportation Services
    Consumer Discretionary

    Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the Company will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. 25th Annual Needham Virtual Healthcare Conference Format: Virtual Corporate presentation Date/Time: Tuesday, April 14, 2026 at 9:30am ET Webcast Link: Precision BioSciences Virtual Presentation Link If you are interested in meeting with the Precision team during the conference, please reach out to your Needham representative. A replay of the presentation wil

    4/8/26 7:01:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

    BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ, the ", Company", )), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement (SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions.

    4/7/26 8:30:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKU
    $AVTX
    $BPTS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Precision BioSciences Inc.

    DEFA14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)

    4/8/26 7:01:42 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Precision BioSciences Inc.

    DEF 14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)

    4/8/26 7:00:28 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by TransCode Therapeutics Inc.

    DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

    4/7/26 8:37:01 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKU
    $AVTX
    $BPTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Avalo Therapeutics with a new price target

    Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00

    4/9/26 8:40:45 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Avalo Therapeutics with a new price target

    Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00

    4/6/26 8:44:25 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKU
    $AVTX
    $BPTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Robins Chad M

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    4/8/26 7:51:17 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Rubinstein Julie

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    4/8/26 7:48:50 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    4/8/26 4:51:43 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKU
    $AVTX
    $BPTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

    For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

    3/5/21 10:37:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $AKU
    $AVTX
    $BPTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Germano Geno J bought $14,160 worth of shares (3,000 units at $4.72), increasing direct ownership by 14% to 23,883 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:02:05 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frankel Stanley bought $12,690 worth of shares (2,700 units at $4.70), increasing direct ownership by 16% to 19,478 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:01:09 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Brown Melinda bought $6,864 worth of shares (1,381 units at $4.97), increasing direct ownership by 6% to 23,346 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:00:53 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $AKU
    $AVTX
    $BPTS
    Financials

    Live finance-specific insights

    View All

    Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

    ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au

    3/31/26 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases

    3/9/26 4:15:00 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures

    2/20/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKU
    $AVTX
    $BPTS
    Leadership Updates

    Live Leadership Updates

    View All

    Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

    ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining

    4/1/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKU
    $AVTX
    $BPTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Blue Star Foods Corp.

    SC 13G/A - Blue Star Foods Corp. (0001730773) (Subject)

    11/14/24 7:34:10 PM ET
    $BSFC

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care